

New Group Rates for 2026! Multiply your team's presence, maximize their impact and minimize costs. Get Your **Rate**.



Earn CLE Credits*

*pending final approval



PCC Pharmaceutical Compliance Congress by informa...

April 27-29, 2026

**The Ritz-Carlton, Tysons Corner
McLean, VA**

The #1 Meeting for Pharmaceutical Compliance — Uniting C-Suite Executives and Senior Leaders

Empower your team from new starters to c-suite with critical enforcement insights, refined strategic compliance approaches and valuable industry connections at PCC.



Lisa LeCointe-Cephas

Chief Compliance Officer,
**Johnson & Johnson
Innovative Medicine**



Anisa Dhalla

Vice President and
Chief Ethics and
Compliance Officer, **UCB**



Isabel Duffy

Senior Vice President,
Chief Ethics and
Compliance Officer,
Merck



Kate Godfrey

Senior Vice President, Global
Chief Compliance Officer,
Karl Storz



Shefali Kothari

Chief Compliance
Officer, US, and Country
Head, Ethics, Risk and
Compliance, **Novartis**



Robert Ladd

Senior Vice President, Chief
Ethics & Compliance Officer,
Gilead Sciences



Melissa Lozner

Senior Vice President,
Chief Compliance
Officer,
Regeneron



**Jill Fallows
Macaluso**

Corporate Vice President
& Chief Compliance
Officer, **Novo Nordisk**



Melanie Polloway

Vice President, Chief Ethics
& Compliance Officer,
Daiichi Sankyo



Leonardo Silva

Vice President, Chief
Compliance & Privacy Officer,
Ferring Pharmaceuticals



Christine Zettlemoyer

Senior Vice President, Global Head
of Compliance, Risk, and Data
Privacy Program, **Genmab**

About the Event

All Access Pass April 27-29, 2026 | McLean, VA


Elevate Your Experience with Dynamic and Impactful Sessions

- **Main Stage Insights:** Gain exclusive guidance on the most pressing issues shaping the entire industry, delivered by renowned thought leaders and experts. Stay ahead of the curve with actionable strategies that impact your organization's success
- **Expert-Led Learning Sessions:** Dive deep into hot topics with industry specialists who will share their expertise, professional perspectives, and practical takeaways to empower your decision-making and drive results
- **Experience-Based Learning:** Access tailored content designed to meet your needs at every level, whether you're just starting out, advancing your career, or leading at the senior level. Enhance your knowledge with sessions crafted for introductory, intermediate, and advanced audiences
- **Power Skills Labs:** Invest in your personal and professional growth with hands-on labs that help you refine critical soft skills, boost your confidence, and advance your career
- **Quick-Fire Use Cases:** Get inspired with three rapid-fire, 10-minute case studies that deliver actionable insights. Learn how industry leaders tackle real-world challenges, uncover upside opportunities, and optimize resources for success
- **Community Conversations:** Engage in thought-provoking discussions and interactive roundtables with peers and experts. Share best practices, explore cutting-edge ideas, and build meaningful connections in a collaborative environment
- **CCO Exchange:** Join an exclusive, invitation-only session for senior Compliance leaders. This advanced programming offers a unique platform to exchange insights, foster high-level peer connections, and address the evolving challenges of top-tier leadership

Each session is designed to deliver maximum value, actionable insights, and opportunities for professional growth, ensuring you leave equipped to make a lasting impact in your role and organization.

Join more than 400 attendees, with over 50% representing over 100 unique (bio)pharmaceutical companies. Connect with a diverse, influential audience of leaders shaping compliance strategies at every level. Whether from a large corporation or a growing company, you'll find peers who share your challenges and opportunities.

Benefit from a mix of seniority guaranteeing strategic conversations and actionable insights from leaders at the forefront of Compliance.



31% CCOs, SVPs, and VPs

28% Directors and Senior Directors

20% Managers, Senior Managers, and Associate Directors

12% Heads of Compliance and Compliance Officers


Attendees span the full spectrum of company sizes, ensuring tailored insights and collaboration opportunities for every business type.

38% from large companies (\$40 billion+)

28% from mid-sized companies (\$30–5 billion)

22% from emerging companies (sub \$1 billion)

12% from small companies (\$0–5 billion)



PCC is more than an event — it's a strategic opportunity to connect with industry leaders, gain valuable insights from diverse perspectives, and position yourself at the forefront of pharmaceutical compliance.



Hit play to dive into the event highlights and discover why this is the must-attend compliance, legal and ethics forum of 2026.

Conference Agenda

Day One — Monday, April 27, 2026

**Please note all times are listed in EDT*

7:30 AM **Conference Registration and Continental Breakfast**

8:30 AM **Informa's Welcome and Chairperson's Opening Remarks**

Audience icebreaker activities during the Chair's opening session
Lisa LeCointe-Cephas, Chief Compliance Officer, Johnson & Johnson Innovative Medicine

8:45 AM **2025 Year in Review Video Reveal, Presented by:** 

8:55 AM **Chief Compliance Officer Panel — Drivers for Change and Challenges for the Year Ahead**

- Compliance department focus: what is in scope for 2026?
- Expanding the compliance umbrella: do trade compliance, privacy, cybersecurity, and enterprise risk now fall under compliance?
- Transparency reporting: should this function sit within compliance or remain under business functions like finance?
- Executive Committee attitudes: are leadership perspectives on compliance evolving, and how are compliance leaders navigating these changes?
- Strategies for resilience: how can compliance leaders prepare for future regulatory challenges in an era of unclear enforcement?
- Agility in compliance programs: how do you keep your program nimble and ready to adapt as priorities shift?
- Influencing organizational decisions: what are effective ways for compliance to shape key decisions directly or indirectly?
- Emerging technologies: how are companies leveraging AI and data analytics to enhance compliance?

Moderator: *Tara McCarthy, Partner, Dovetail Consulting Group*

Isabel Duffy, Senior Vice President, Chief Ethics and Compliance Officer, Merck

Melissa Lozner, Senior Vice President, Chief Compliance Officer, Regeneron

Robert Ladd, Senior Vice President, Chief Ethics & Compliance Officer, Gilead Sciences

9:45 AM **Federal US DOJ Keynote**

- What should Life Science companies be focused on around combatting fraud, waste, and abuse?
- Expectations around AI governance
- Updates to Compliance program guidance

10:15 AM **Networking and Refreshment Break**

10:45 AM **Prosecutor Panel: The Big Picture in Life Science Enforcement**

- Hear directly from U.S. Attorneys on the most recent CIA's and an analysis of settlement trends
- Areas currently being closely looked at by investigators?
- What methods, analysis, and data are being utilized during investigations?
- Has the Blanche Memo led to an increase in cases?
- SEC perspective and priorities

Moderator: *Craig Bleifer, Partner, McGuireWoods*

Mackenzie Queenin, Assistant US Attorney and Chief, Health Care Fraud, US Attorney Office, District of Massachusetts (subject to final approval)

11:45 AM	Federal Trade Commission Update • Where do their current enforcement priorities lie? • Are there any practices that Compliance leaders should be on the lookout for within their organizations? • Will there be a ramp-up on how good enter/exit the US in light of the administration and the direction they are going?		
12:15 PM	Analyzing the False Claims Act Working Group: Focus and Actions • DOJ-HHS-CMS partnerships enforcement priorities • Latest updates from the working group and what Life Science organizations should be doing proactively		
12:45 PM	Networking Luncheon		
	Tracked Sessions Experience Based Sessions: Tailored Content to Enhance Learning and Drive Opportunities to Build New Support Networks with Peers		
	Foundation	Intermediate	Senior
2:15 PM	Compliance Bootcamp: Compliance Readiness Framework • Establish a foundation of Compliance using the seven elements of a Compliance framework • Are all Compliance programs the same? Building a program for a start-up vs. a fully commercialized organization • Examining the three foundational questions in the DOJ Evaluation of Effective Compliance Programs • Reality of operationalise your Compliance program: resources needed for implementation, realities of monitoring and auditing, pragmatic approaches to new trends and risks <i>Stephanie Macholtz, Vice President, Healthcare Compliance, Organogenesis</i>	Best Practice for Investigations, Whistleblower Incentives & Protections • New ideas and solutions to investigator challenges • Practical tools and tips for handling difficult investigations and joint working with Legal/HR • How are investigation outcomes shared with the organization? • Providing clear, C-suite-endorsed messaging that encourages internal reporting • Strengthening internal complaint pathways in addition to anonymous reporting options • Approaches for responding to hotline reporters <i>Melanie Polloway, Vice President, Chief Ethics & Compliance Officer, Daiichi Sankyo</i> <i>Beth Reiley, Head of Investigations Global Compliance, Viatis</i>	From Compliance Leader to Board Member: Elevating Your Strategic Impact • Understanding the different types of Board opportunities and positions and what is required for each • Overview of HHS-OIG's expectations and recommendations for Board oversight of ethics and compliance • Essential competencies: critical skills and experiences that help compliance leaders transition to board service • Writing your Board resume: understanding elements will help you stand out • Building your board profile: developing the visibility, network, and credentials that open boardroom doors • Tools and tips for running a compliance committee that align with HHS-OIG Guidance Moderator: <i>Mahnu Davar, Partner, Arnold & Partner</i> <i>Sujata Dayal, Independent Board Director, Emergent BioSolutions</i> <i>Felicia Heimer, Head of Rare Disease Compliance, Amgen; Co-Author of OIG's Practical Guidance for Health Care Governing Boards on Compliance Oversight</i>

	Foundation	Intermediate	Senior
3:00 PM	POWER SKILLS LAB Compliance Career Development • Differing phases of your career: explore career development across different stages • Learn about essential technical and soft skills necessary for success in compliance, including legal knowledge, communication, problem-solving and increasingly the data analytics • Understand the importance of mentorship, networking, and professional connections in shaping career progression and uncovering new opportunities • Effectively position yourself for recruiters and hiring managers • Understanding the nuances of different roles and how to tailor your approach to align with expectations • How to ask for new opportunities: practical advice on identifying and pursuing new opportunities within your organization or industry <i>Joe Philipose, Senior Vice President, Chief Ethics and Compliance Officer, Emergent BioSolutions</i> <i>Andrea Kocharyan, Vice President, Legal Counsel Commercial, uniQure</i>	Documenting Compliance: Protecting Your Program Before You're Under the Microscope • The importance of documenting your compliance program: practical dos and don'ts • Does your documentation hold up to potential scrutiny such as litigation? • Interplay between legal and compliance • What needs to be privileged? Is privilege compliance documentation a help or hinderance when protecting company against litigation and where is the line? Moderator: <i>Casey Horton, Managing Director, Epsilon Life Sciences</i> <i>Grant Ostlund, Senior Director - Strategy & Operations, Ethics & Compliance, Novo Nordisk</i> <i>Saul Helman, President, Epsilon Life Sciences</i>	Compliance Capabilities for the Future • Scope of your compliance — What sits at the core of a compliance program? • Evaluating current team capabilities against future skill requirements • Skills needed for your program: considering outsourcing, offshoring, automation, local workforce etc. • Technical solutions: to what extent can automation help? • Upskilling your workforce: considering the traditional background skills for compliance, what new skill sets do you need to instil or seek out? • Managing prioritization for new skills: Compliance manager vs data scientist – how do you sell benefits between one or another? <i>Shefali Kothari, Chief Compliance Officer, US, and Country Head, Ethics, Risk and Compliance, Novartis</i>
3:45 PM	Networking and Refreshment Break		

GET SOCIAL
#PCC2026
informa •••



Community Conversations: Thought Leadership Alongside Interactive Roundtable Sessions

Led by subject matter experts who will share the latest thinking, community conversations offer a unique opportunity to gain both cutting-edge insights alongside the perfect opportunity for meaningful peer exchanges, share working practices and extend your network.

4:15 PM

POWER SKILLS LAB **Empowering Compliance Professionals: Mastering Data Literacy for Future Success**

- Why Compliance professionals must upskill their data literacy
- Key advice and common trip points for data ethics, data systems and mapping data flow within your organization
- Tools to help you advance your data analytics output and insights
- How data can underpin compliance conversations and amplify your message: powerful tools to strengthen compliance-related discussions

Bryan Timer, Executive Director, Innovation, Digital Enablement, and Analytical Solutions, Merck

Aaron Leskow, Associate Director of Healthcare Compliance, Immunocore

R&D Compliance Risks Under the False Claims Act

- Interpreting the latest EO and DOJ guidance impacting R&D
- Examining HCP interactions under R&D
- Examining risk exposure and approaches to designing policies to mitigate risk

Moderator: *Nikki Reeves, Partner, King & Spalding*

Roberta Rima, Vice President, Global Compliance Audit, Monitoring, Analytics, Zimmer Biomet

Evaluating Program Effectiveness

- How are you tying the different elements of your compliance program together?
- Who and how to measure the effectiveness of your Compliance program
- How do you then identify what is driving lower scores so that you can effectively manage that particular risk?

Evidencing continual growth to your Executives and Board
Al Park, Global Program Effectiveness & Insights Leader, Worldwide Compliance & Business Ethics, Amgen

Kelly Tope, Head of Ethics and Business Integrity Governance, Operations & Risk Management NA & Global Specialty Care, Sanofi

CCO EXCHANGE AND HAPPY HOUR

Exclusive Invitation-Only Event for Senior Compliance Leaders

This private gathering is designed exclusively for the most senior Compliance leaders, offering a unique opportunity to share insights, foster meaningful peer connections, and engage in advanced programming tailored to the evolving challenges of top Compliance leadership. Key Features:

- Confidential Peer Discussions: Engage in open and secure conversations with fellow leaders
- Leadership-Focused Discussion: Participate in sessions designed to address strategic leadership challenges
- Forward-Thinking Insights: Explore innovative approaches and future trends in leadership

Facilitators: *Jill Fallows Macaluso, Corporate Vice President & Chief Compliance Officer, Novo Nordisk*

Donna White, Vice President, Compliance U.S., Chiesi US

5:00 PM	Advancing Monitoring - Strategies and tactics on what should be monitored - Best practice for live monitoring activities - Role of data analytics in monitoring programs - Advancing monitoring activities across the business: reframing monitoring to business insight gathering - How can audit and monitoring work together in partnership? Moderator: Jeff Hyre, Vice President of Sales - Healthcare & Life Sciences, Global Relay Yvonne Osirim, Vice President, Human Health Ethics & Compliance, Merck Christine Zettlemoyer, Senior Vice President, Global Head of Compliance, Risk, and Data Privacy Program, Genmab	The Interplay between Compliance, Legal and Regulatory Teams - Common trip points and cross-functional working - How to clearly define the difference between Legal, Compliance, and Regulatory risk David Ryan, Vice President, Legal, and Chief Compliance Officer, Ardelyx	Are You Overcomplicating Your Risk Assessments? - Tools to simplify your risk assessments, focus on what truly matters, and leverage them as a powerful driver of Compliance - How to adapt your risk assessment approach based on company size, pre-commercial or commercial, and aligned with your operational realities - From paper to practice: turning risk assessments into action plans - Practical tips to get the most value from your risk assessment process - Benchmarking risks to track progress and trends over time Colleen Doyle, Senior Risk Director, Risk Insight & Management, Novo Nordisk Erica Powers, Former Vice President, Chief Compliance Officer, Sage Therapeutics	CCO EXCHANGE AND HAPPY HOUR (Continued) Eligibility: Attendees must hold the position of Chief Compliance Officer (CCO) / Head of Compliance or Vice President (VP) and be currently employed by a life sciences manufacturer. Invitations for this session will be sent to attendees closer to the event. To secure your spot and ensure your participation, please email Leena Shaw at leena.shaw@informa.com
---------	--	--	--	---

5:45 PM	Close of Day One and Networking Reception
---------	--

Day Two — Tuesday, April 28, 2026

*Please note all times are listed in EDT

7:30 AM	Continental Breakfast
8:20 AM	Chairperson's Review of Day One Audience icebreaker activities during the Chair's opening session. Lisa LeCointe-Cephas, Chief Compliance Officer, Johnson & Johnson Innovative Medicine
8:40 AM	Global Compliance Officers Panel: Navigating Global Ethics and Compliance in the Face of Transformative Enforcement Shifts - FCPA takeaways for updating risk management, internal investigations and compliance strategies - Navigating tariffs and sanctions - how are compliance teams adapting to new geoeconomic trends - What does it now take to manage a global team, keep everyone on the same page and tackle compliance calls? - Establishing compliance standards across varied geographies: developing a core program with regional flexibility Kate Godfrey, Senior Vice President, Global Chief Compliance Officer, Karl Storz Leonardo Silva, Vice President, Chief Compliance & Privacy Officer, Ferring Pharmaceuticals Anisa Dhalla, Vice President and Chief Ethics and Compliance Officer, UCB Maurice Cresenzi, Jr., Industry Practice Leader, Moody's Analytics, Inc.

9:30 AM	KEYNOTE CCO Organizational Value of Compliance • How do you define compliance value? • What really matters to the Board, when showcasing the value of Compliance? • Translating compliance activities into performance <i>Jill Fallows Macaluso, Corporate Vice President & Chief Compliance Officer, Novo Nordisk</i>
10:10 AM	OIG's Compliance Crosshairs: What Pharma Must Prioritize Now • Decoding OIG enforcement: scrutinizing recent OIG settlements and their implications • Turning guidance into controls: aligning programs with OIG's guidance and recent advisory opinions <i>Meredith Williams, MW Associates PLLC, Former Senior Counsel, Office of Counsel to the Inspector General of the U.S. Dept. of Health & Human Services, Former Senior Counsel, HHS Office of Inspector General</i> <i>Felicia Heimer, Head of Rare Disease Compliance, Amgen, and Former Deputy Chief, HHS Office of Inspector General</i>
10:50 AM	Networking and Refreshment Break
11:20 AM	Former Prosecutors Panel: Interpreting the Latest DOJ Actions and Investigations • Commentary on the latest developments from DOJ • Update on DOJ's health care fraud, FCPA, and other corporate enforcement • DOJ guidance to prosecutors and its significance for pharmaceutical companies • The current state of False Claims Act litigation <i>Amanda Masselam Strachan, Partner, Wilmer Hale</i> <i>Lee Cortes, Partner, Arnold & Porter</i>
12:00 PM	Law Firm Benchmarking Session: Chairs of Life Science Groups in Law Firms • Analysis of the most recent Executive Orders impacting (Bio)pharmaceutical companies • Implications of the Big, Beautiful Bill and Most Favoured Nations Pricing • Does 'deregulation' mean more or less enforcement for the pharmaceutical sector? • Litigation against the Administration <i>Stefanie Doeblér, Partner, Covington</i> <i>Scott Liebman, Partner, Sheppard Mullin</i>
12:50 PM	Networking Luncheon

Topic Intensives

2:20 PM

QUICK FIRE USE CASE

Disruption: Reinventing Compliance Through Applied AI

Compliance is shifting from dashboards to decisions, from detection to prevention. This session spotlights how leading organizations are using AI to transform fragmented audit, monitoring and investigations data into actionable insights that drive faster, smarter risk decisions. Through real-world case studies, we'll explore what's working now and what's next. You'll hear how companies are:

- Using AI-driven analytics to flag anomalies, detect emerging risks, and optimize field and digital monitoring
- Turning disparate data into prioritized risk insights that guide proactive action
- Building right-sized, cost-effective AI capabilities across pharma and biotech
- Leveraging automation to reduce investigation time, cut costs, and improve accuracy
- Harnessing predictive analytics and GenAI to shape the future of compliance operations

Michael Shaw, Principal, Global Head - Compliance, Privacy & Risk, ZS

ADVANCED

Global Harmonization of Compliance Standards: How Can Compliance Officers Align Across U.S., EU and APAC Frameworks?

- Practical experience of navigating across different regions
- Strategies for ensuring organizational compliance effectiveness

Suki Wiltman, Vice President, Global Ethics & Compliance, Ipsen Biopharmaceutical (subject to final confirmation)

David Falcone, Vice President, Global Compliance, Merz Aesthetics

Kirt Kraeuter, Executive Director, ERC Advisory, Policy & Learning, Novartis

QUICK FIRE USE CASE

Successful Compliance Communication Strategies in Action

Get inspired with three rapid-fire, 10-minute case studies that deliver actionable insights. Learn how industry leaders tackle real-world challenges, uncover upside opportunities, and optimize resources for success.

Heather McCollum, Vice President, Compliance, Shionogi

Jennifer Sanfilippo, General Counsel and Chief Compliance Officer, Melinta Therapeutics

James Accumanno, Vice President, Legal & Chief Compliance Officer, Karyopharm Therapeutics

3:10 PM

Afternoon Networking Break

3:50 PM

Guardrails for Evolving Field Facing Roles

- How can we ensure we are communicating in every way we can communicate whilst remaining compliant?
- Interactions with GPOs: examining the types of interactions with field roles, what they can talk about and what can they do
- Medical commercial interactions: helping Compliance keep pace with agile approaches
- Considerations when using scientific platforms to engage HCPs

Moderator: *Kimberly Gregorio, Vice President, P360*

Rore Middleton, Vice President, Compliance and Ethics, Blueprint Medicines

Peter Agnoletto, 'Ethics and Business Integrity Global Head for aT1D&CVM Franchise and US General Medicines Strategic Advisor, General Medicines and Consumer Healthcare, Sanofi

Alicia Whittlesey, Partner, Porzio, Bromberg & Newman

ADVANCED SIUU

Scientific Information on Unapproved Use(s) of Approved Medical Product Communications

- Nuances for communications for unapproved use of approved products
- What are people doing in the field? What is being allowed to be shared by Medical Science Liaison professionals (MLS) and practical guardrails that can be put into place

Leonardo Silva, Vice President, Chief Compliance & Privacy Officer, Ferring Pharmaceuticals

Mihaela Carsin, Compliance Business Lead, AstraZeneca

QUICK FIRE USE CASE

Practical Training Ideas to Implement in your Organization

Get inspired with three rapid-fire, 10-minute case studies that deliver actionable insights. Learn how industry leaders tackle real-world challenges, uncover upside opportunities, and optimize resources for success.

Moderator: *Daniel O'Connor, Senior Vice President, NXLevel Compliance*

Rachel Batykefer, Vice President, CIA and Compliance Operations, Mallinckrodt Pharmaceuticals

4:55 PM	QUICK FIRE USE CASE Success Stories in Data Analytics Get inspired with three rapid-fire, 10-minute case studies that deliver actionable insights. Learn how industry leaders tackle real-world challenges, uncover upside opportunities, and optimize resources for success. <i>Sarah Venable, Head of Data Science and Risk Analytics, GSK</i> <i>Bryan Timer, Executive Director, Innovation, Digital Enablement, and Analytical Solutions, Merck</i>	ADVANCED Connecting Compliance and Holistic Risk Management • Compliance's role in strategic risk leadership • Risk intelligence: translating compliance knowledge into strategic decision-making frameworks • How to work collaboratively and cross functionally • How is risk management informed by own monitoring and data, and all integrate together • How are people handling risk assessment process: new ways of working Moderator: <i>Eric Baim, Partner, Dovetail Consulting Group</i> <i>Jackie Stanley, Digital, AI, and Privacy Compliance Team, Pfizer</i> <i>Blair Shaw, Vice President & Senior Compliance Officer, Cencora</i>	Market Access Risk Areas • Navigating the payer and lobbying landscape for the Life Science industry • Understanding areas of risk for market access activities • Interplay between commercial teams, market access teams and Compliance • Developing risk mitigation strategies Moderator: <i>Margaux Hall, Partner, Ropes & Gray</i> <i>Karen Lowney, Head of the Office of Ethics & Compliance (OEC), Sun Pharmaceutical</i> <i>Brandon Goodman, Vice President Legal, Global & Market Commercialization, BioNTech US</i>
---------	---	--	---

5:40 PM	Close of Day Two Followed by Networking Reception		
---------	--	--	--

Day Three — Wednesday, April 29, 2026 *Please note all times are listed in EDT			
--	--	--	--

7:30 AM	Registration and Continental Breakfast		
8:30 AM	Compliance Considerations for Buy & Bill Products • Variety of risks and regulatory pitfalls present in Buy and Bill products <i>Timothy Roberts, Global Chief Compliance Officer, Legend Biotech</i> <i>Sarah Whipple, Vice President, Global Chief Compliance Officer, Apellis Pharmaceuticals</i>	Developments for Diagnostic Support Programs • Update DOJ and OIG on free testing • Implications for wider diagnostic testing • Anti-kickback risks • Implications of recent OIG opinion on one-time genetic test or treatment approval • What the relationships look like for diagnostics and labs <i>Catherine Kaucher, Health Care Compliance Officer, Johnson & Johnson</i> <i>Alexis Shaw, Deputy Chief Compliance Officer, Paratek Pharmaceuticals</i>	Navigating Data Privacy: What Compliance Professionals Need to Know • Privacy essentials for pharmaceutical companies • How do you set up privacy programs considering the varying privacy requirements and an ever-changing landscape? • As privacy considerations grow for your business, where does it sit and how do you operationalize it? Compliance vs. Legal department vs. independent privacy officer? Moderator: <i>Erin Wagenberg, Director, Dovetail Consulting Group</i> <i>Danielle Green, Senior Director, Legal & Compliance, Savara</i>

9:15 AM	Commercial Risks in Patient Support Programs • How businesses co-ordinate patient support and the relationship between commercial teams and patients • Examining different roles engaging with patients including Nurse Educators, Patient Education Liaison, and Patient Advocacy groups • Practical compliance considerations for Patient Speaker programs and Patient Ambassador Program • Examining differing approaches on transfer of value in meals, speaker honorarium etc • Internal guidelines and spend for patients, and practical questions such as if alcohol is allowed etc? <i>Brian Sharkey, Head, US Compliance and Ethics, Teva Pharmaceuticals</i> <i>Chetan Shankar, Senior Director Ethics & Compliance, Senior Director Ethics & Compliance, Veloxis Pharmaceuticals</i>	Embedding Compliance into Organizational Culture • Understanding the DOJ and FCPA focuses for compliance culture • How do you measure the culture of compliance? • How to cultivate a culture of Compliance • How do you become ‘the voice’ of Ethics and Integrity in your organization? • Ethical conduct with compliance — understanding group think, deviance etc <i>Natasha Trifun, Head of Enterprise Compliance & Risk, AstraZeneca</i> <i>Elizabeth Weiss, Vice President, Chief Compliance and Privacy Officer, Invivyd</i> <i>Maria Villanueva, Director, Ethics and Compliance, BioTissue</i>	Navigating Social Media • Fundamentals of a social media policy • What are your guardrails and parameters on influencers • Social media personalities and FMV • Commercial teams on social media — Where is the line when posting, liking and reposting? • How do you monitor social media? 3rd party? Monitoring via AI? • Global risks eg EU/ABHI <i>Derek Frueh, Head of NA Compliance & Canadian General Counsel, Leo Pharma</i> <i>Averi Price, Senior Vice President, Legal, Chief Compliance Officer, Syndax</i>
10:00 AM	Networking and Refreshment Break		
Main Stage			
10:30 AM	Transforming Compliance Data into a Strategic Asset: Macro Trends and Outlier Patterns • How are you supporting the business with your compliance data? • Shifting the perception of compliance data from a regulatory obligation to a tool for driving business performance and protecting enterprise value • Utilizing analytics to demonstrate how compliance initiatives contribute to operational success • How to share compliance data effectively across teams, including sales and commercial, with clear purposes and transparency • Can compliance data help identify macro trends and areas requiring attention: connecting compliance softness and performance Moderator: <i>Brook Mishler, Global Director Compliance Solutions - Life Sciences, CaseIQ</i> <i>Marcus Green, Vice President, Risk Analytics and Monitoring, GSK</i> <i>Piyush Sharma, Chief Ethics & Compliance Officer, Alnylam Pharmaceuticals</i> <i>Jennifer Beaudoin, Executive Director, Head of Global Compliance Program Strategy, Assurance & Management, Vertex</i> <i>Daryl Kreml, Head of Ethics and Compliance, Takeda Oncology</i>		

11:20 AM	KEYNOTE Key FDA Developments for Drug Advertising and Practical Compliance Take Aways • Insight into the current priorities at the FDA and their scrutiny on consumer-facing promotion • Appetite for a sustained shift in enforcement activity • Regulators' insight into the monitoring activities undertaken by organizations and the use of AI and social media
11:50 AM	Transparency Reporting: Centers for Medicare & Medicaid Services (CMS) Open Payments Program • Update on State transparency reporting • Developments in audits: are we going to see more scrutiny in what companies are doing? What do we need to be doing differently going forward? • Data insight: how do regulators and investigators use the data? How can companies ensure they know what is in the data and what should they expect regulators to know about their data?
11:20 PM	The Ripple Effects of a Shifting Payer Landscape on Compliance • Impact of recent legislative and administrative developments on drug pricing, reimbursement, and access • PBMs on shaky ground: examining the instability of Pharmacy Benefit Managers and its implications for the healthcare ecosystem • Rebates and Pharma Impact: understanding how rebate changes will primarily affect pharmaceutical companies and spill over into the medical device sector via GPOs • Implications of provider sector challenges: consequences of rising premiums and the growing physician exodus as the provider sector reaches a tipping point • Industry-wide implications: highlighting how the evolving payer and provider dynamics directly impact Life Sciences companies and their stakeholders <i>Meena Datta, Healthcare & Life Sciences Co-Chair, Executive Committee Member, Sidley</i>
11:50 PM	PhRMA (Pharmaceutical Research and Manufacturers of America) Address • Impact of recent legislative and administrative developments on drug pricing, reimbursement, and access <i>James Stansel, Executive Vice President, General Counsel and Corporate Secretary, PhRMA</i>
12:20 PM	Close of Conference

GET SOCIAL
#PCC2026
informa...



Sponsors & Exhibitors

Bronze Sponsor



Associate Sponsor



Supporting Sponsors




Buchanan

Case IQ

COVINGTON



epsilon
life sciences



McGuireWoods

MOODY'S



ROPES & GRAY



SIDLEY

WILMERHALE 



A Great Place to Meet Your Market!

Maximize your access to decision-makers and align your brand with the life sciences industry's premier thought-leaders and industry innovators. Informa Connect's custom sponsorship programs are designed to support your organization's overall business development and marketing initiatives through meaningful prospect and customer interactions, brand assertion campaigns and content-rich thought-leadership opportunities. Capitalize on the life sciences community's premier platform for peer-to-peer exchange, solution driven content and first-in-class networking opportunities.

For more information on how to position your company as a sponsor or exhibitor, contact:



Derek Tagliarino • 212-600-3433
derek.tagliarino@informa.com

Registration

REGISTRATION FEE	Book by 1/23/2026	Standard Rate
Life Sciences Manufacturers	\$2599	\$3199
Small & Medium Enterprise (SME)	\$1999	\$2699
Solution Providers / Consultants / Law Firms	\$3599	\$4199

4 Ways to Register Now!



WEB

informaconnect.com/pcc



PHONE

+1 646-814-9096



LIVE CHAT

informaconnect.com/pcc



EMAIL

ruhed.miah@informa.com

Your Key Points of Contact:



Content Development:

Leena Shaw

+44 20 8052 0623

leena.shaw@informa.com



Sponsorship & Exhibits:

Derek Tagliarino

+1-212-600-3433

derek.tagliarino@informa.com



Registration & Groups

Ruhed Miah

+1 646-814-9096

ruhed.miah@informa.com

CLE Credits

This event is eligible for CLE credits. CLE credits are only available for All-Access (In-Person) attendees. CLE credits will only be awarded to sessions watched live at the conference. Sessions watched On-Demand at a later date are not eligible for CLE credits. For more information please visit the CLE credits tab on the Pharmaceutical Compliance Congress website.

Venue Information

The Ritz-Carlton, Tysons Corner

1700 Tysons Boulevard

McLean, VA 22102

Hotel Direct Line: +1-703-506-4300

Accommodations

For hotel room availability and direct booking links, please visit the conference website and select the [plan your visit tab](#). Rooms are limited so please book early. All travel arrangements are subject to availability.

Media Partners:



Pharmaceutical
Executive

PHARMACEUTICAL
COMMERCE

pharma
marketing

RC RADICAL COMPLIANCE
CRAFT TRAINING ABOUT COMPLIANCE, AVOID AND USE

